Protocol Page


	Study ID (Protocol Number)
	CA204-009


	STUDY LOCATIONS*
	Cancer Care Specialists Of Central Illinois Decatur, IL 62526 Recruiting	Carle Cancer Center Urbana, IL 61801 Recruiting
	Cancer Center Of Acadiana Lafayette, LA 70503 Recruiting	Compassionate Cancer Care Medical Group, Inc Corona, CA 92879 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
	STUDY OVERVIEW
	The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will increase the time before myeloma worsens [progression free survival (PFS)].

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.